Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery

Biotechnology Progress

Volumn 24, Issue 4, 2008, Pages 945-956

  Zhang, Sufeng ^a   Wang, Guilin ^a   Lin, Xiaoyue ^a   Chatzinikolaidou, Maria ^b,c   Jennissen, Herbert P ^d   Laub, Marcus ^d   Uludaǧ, Hasan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Albumin nanoparticles; Bone morphogenetic protein 2; Controlled release; Polyethylenimine

Indexed keywords

ALBUMIN NANOPARTICLES; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN-2; BOVINE-SERUM ALBUMIN; COLLOIDAL SYSTEMS; CONTROLLED RELEASE; ELECTROSTATIC ADSORPTION; ENCAPSULATION EFFICIENCY; GROWTH FACTORS; IN VITRO RELEASES; IN-VIVO; MTT ASSAYING; POLYETHYLENIMINE; RELEASE RATES; SUSTAINED RELEASE; ZETA-POTENTIAL MEASUREMENTS;

ADSORPTION; ATOMIC FORCE MICROSCOPY; BONE; CLADDING (COATING); CONCENTRATION (PROCESS); DRUG PRODUCTS; ENCAPSULATION; IMAGING TECHNIQUES; MICROSCOPIC EXAMINATION; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; NUCLEAR PROPULSION; SCANNING PROBE MICROSCOPY; TOXICITY; ZETA POTENTIAL;

BODY FLUIDS;

BONE MORPHOGENETIC PROTEIN 2; BOVINE SERUM ALBUMIN; METAL NANOPARTICLE; NANOCAPSULE; POLYETHYLENEIMINE;

ANIMAL; BIOAVAILABILITY; CATTLE; CELL LINE; CHEMISTRY; CONFERENCE PAPER; EVALUATION; KINETICS; METHODOLOGY; MOUSE; ULTRASTRUCTURE;

ANIMALS; BIOLOGICAL AVAILABILITY; BONE MORPHOGENETIC PROTEIN 2; CATTLE; CELL LINE; CHEMISTRY, PHARMACEUTICAL; KINETICS; METAL NANOPARTICLES; MICE; NANOCAPSULES; POLYETHYLENEIMINE; SERUM ALBUMIN, BOVINE;

BOVINAE;

EID: 51849156347     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1002/btpr.12     Document Type: Conference Paper

References (56)

1. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone: biology and clinical applications. J Bone Joint Surg Am. 2002;84:1032-1044.
2. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528-1534.
3. Yasko AW, Lane JM, Fellinger EJ, Rosen V, Wozney JM, Wang EA. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein rhBMP-2. A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg Am. 1992;74:659-670.
4. Bostrom M, Lane JM, Tomin E, Browne M, Berberian W, Turek T, Smith J, Wozney J, Schildhauer T. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop. 1996;327:272-282.
5. Gerhart TN, Kirker-Head CA, Kriz, MJ, Holtrop ME, Hennig GE, Hipp J, Schelling SH, Wang E. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop. 1993;293:317-326.
6. Sciadini MF, Johnson KD. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res. 2000;18:289-302.
7. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev. 1997;8:11-20.
8. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg. 2006;88:1431-1441.
9. Khan SN, Bostrom MPG, Lane JM. Bone growth factors. Orthop Clin North Am. 2000;31:1-14.
10. Luginbuehl V, Meinel L, Merkle HP, Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm. 2004;58:197-208.
11. Maeda H, Sano A, Fujioka K. Controlled release of rhBMP-2 from collagen minipellet and the relationship between release profile and ectopic bone formation. Int J Pharm. 2004;275:109-122.
12. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Delivery Rev. 2003;55:1613-1629.
13. Putney SC, Burke P. Improving protein therapeutics with sustained-release formulations. Nature Biotech. 1998;16:153-157.
14. Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. Development of poly-D,L-lactide-co-glycolide microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release. 2001;72:13-24.
15. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21:387-422.
16. Chen F, Wu Z, Sun H, Wu H, Xin S, Wang Q, Dong G, Ma Z, Huang S, Zhang Y, Jin Y. Release of bioactive BMP from dextran-derived microspheres: a novel delivery concept. Int J Pharm. 2006;307:23-32.
17. Jiang B, Gao C, Hu L, Shen J. Water-dispersed bone morphogenetic protein nanospheres prepared by co-precipitation method. Zhejiang Univ SCI. 2004;5:936-940.
18. Arshady R. Albumin microspheres and microcapsules: methodology of manufacturing techniques. J Control Release. 1990;14:111-131.
19. Morimoto Y, Fujimoto S. Albumin microspheres as drug carriers. Crit Rev Ther Drug Carrier Syst. 1985;2:19-63.
20. Rhodes BA, Zolle I, Buchanan JW, Wagner HN Jr. Radioactive albumin microspheres for studies of the pulmonary circulation. Radiology. 1969;92:1453-1460.
21. Praveen Reddy B, Dorle AK, Krishna DR. Albumin microspheres: effect of process variables on size distribution and invitro release. Drug Dev Ind Pharm. 1990;16:1791-1803.
22. Das S, Banerjee R, Jayesh B. Aspirin loaded albumin nanoparticles by coacervation: implications in drug delivery. Trends Biomater Artif Organs. 2005;18:203-212.
23. Lin W, Coombes AGA, Davies MC, Davis SS, Ilium L. Preparation of sub-100 nm human serum albumin nanoshperes using a pH-coacervation method. J Drug Targeting. 1993;1:237-243.
24. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci. 2001;12:251-259.
25. Leo E, Vandelli MA, Cameroni R, Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process. Int J Pharm. 1997;155:75-82.
26. Segura S, Gamazo C, Irache JM, Espuelas E. Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus. Antimicrob Agents Chemother; 2007;51:1310-1314.
27. Segura S, Espuelas S, Renedo MJ, Irache JM. Potential of albumin nanoparticles as carriers for interferon gamma. Drug Dev Ind Pharm. 2005;31:271-280.
28. Chatzinikolaidou M, Zumbrink T, Jennissen HP. Stability of surface-enhanced ultrahydrophilic metals as a basis for bioactive rhBMP-2 surfaces. Materialwiss Werkstofftech. 2003;34:1106-1112.
29. Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin nanoparticles. Int J Pharm. 2003;257:169-180.
30. Lin W, Garnett M, Davies MC, Bignotti F, Ferruti P, Davis SS, Illum L. Preparation of surface-modified albumin nanospheres. Biomaterials. 1997;18:559-565.
31. Rahimnejad M, Jahanshahi M, Najafpour GD. Production of biological nanoparticles from bovine serum albumin for drug delivery. Afr J Biotechnol. 2006;5:1918-1923.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
33. Zhang S, Wright JEI, Özber N, Uludag H. The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite. Macromol Biosci. 2007;7:656-670.
34. Gittens SA, Bansal G, Kucharski C, Borden M, Uludag H. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes. Mol Pharm. 2005;2:392-406.
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
36. Varkey M, Kucharski C, Takrima H, Sebald W, Uludag H. In vitro osteogenic response of rat bone marrow cells to bFGF and BMP-2 treatments. Clin Orthop Relat Res. 2006;443:113-123.
37. Willmott N, Cummings J, Florence AT. In vitro release of adriamycin from drug-loaded albumin and haemoglobin microspheres. J Microencapsulation. 1985;2:293-304.
38. Park TG, Cohen S, Langer R. Controlled protein release from polyethyleneimine-coated poly L-lactic acid/pluronic blend matrices. Pharm Res. 1992;9:37-39.
39. Kim IS, Lee SK, Park YM, Lee YB, Shin SC, Lee KC, Oh IJ. Physico-chemical characterization of poly-L-lactic acid and poly-D,L-lactide-co-glycolide nanoparticles with polyethylenimine as gene delivery carrier. Int J Pharm. 2005;298:255-262.
40. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm. 2000;194:91-102.
41. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nano-particles: theory to practice. Pharmacol Rev. 2001;53:283-318.
42. Thassu D, Deleers M, Pathak Y. Nanoparticulate Drug Delivery Systems. New York, USA: Informa Healthcare; 2007:51-99.
43. Plank C, Mechtler K, Szoka FC Jr., Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996;7:1437-1446.
44. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93-102.
45. Devine DV, Wong K, Serrano K, Chonn A, Cullis, PR. Liposome complement interactions in rat serum: implications for liposome survival studies. Biochim Biophys Acta. 1994;1191:43-51.
46. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res. 1994;11:402-406.
47. Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 1999;448:193-196.
48. Roser M, Fidher D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II. Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 1998;46:255-263.
49. Huang M, Vitharana SN, Peek LJ, Coop T, Berkland C. Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor. Biomacromolecules. 2007;8:1607-1614.
50. Tiyaboonchai W, Woiszwillo J, Sims RC, Middaugh CR. Insulin containing polyethylenimine-dextran sulfate nanoparticles. Int J Pharm. 2003;25:139-151.
51. Tiyaboonchai W, Woiszwillo J, Middaugh CR. Formulation and characterization of amphotericin B-polyethylenimine-dextran sulfate nanoparticles. J Pharm Sci. 2001;90:902-914.
52. Uludag H, D'Augusta D, Golden J, Li J, Timony G, Riedel R, Wozney JM. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. i Biomed Mater Res. 2000;50:227-238.
53. Rhaese S, Von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K. Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release. 2003;92:199-208.
54. Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Delivery Rev. 2006;58:1523-1531.
55. Boeckle S, Von Gersdorff K, Van der Piepen S, Culmsee C, Wanger E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med. 2004;6:1102-1111.
56. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev Biol. 1994;161:218-228.